Thomas D Barbour

List of Publications by Year
in descending order

23	800	840585 11	713332 21
papers	citations	h-index	g-index

24	24	24	1026
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Atypical aHUS: State of the art. Molecular Immunology, 2015, 67, 31-42.	1.0	236
2	Thrombotic microangiopathy and associated renal disorders. Nephrology Dialysis Transplantation, 2012, 27, 2673-2685.	0.4	168
3	Recent insights into C3 glomerulopathy. Nephrology Dialysis Transplantation, 2013, 28, 1685-1693.	0.4	70
4	An extended mini-complement factor H molecule ameliorates experimental C3 glomerulopathy. Kidney International, 2015, 88, 1314-1322.	2.6	58
5	Dense Deposit Disease and C3 Glomerulopathy. Seminars in Nephrology, 2013, 33, 493-507.	0.6	57
6	Update on C3 glomerulopathy. Nephrology Dialysis Transplantation, 2016, 31, 717-725.	0.4	52
7	Long-Term Efficacy and Safety of the Long-Acting Complement C5 Inhibitor Ravulizumab for the Treatment of Atypical Hemolytic Uremic Syndrome in Adults. Kidney International Reports, 2021, 6, 1603-1613.	0.4	29
8	Consensus opinion on diagnosis and management of thrombotic microangiopathy in Australia and New Zealand. Internal Medicine Journal, 2018, 48, 624-636.	0.5	26
9	Antiphospholipid syndrome in renal transplantation. Nephrology, 2014, 19, 177-185.	0.7	21
10	Consensus opinion on diagnosis and management of thrombotic microangiopathy in Australia and New Zealand. Nephrology, 2018, 23, 507-517.	0.7	21
11	Management of refractory lupus nephritis: challenges and solutions . Open Access Rheumatology: Research and Reviews, 2019, Volume 11, 179-188.	0.8	17
12	Long-term outcomes of kidney transplant recipients with end-stage kidney disease attributed to presumed/advanced glomerulonephritis or unknown cause. Scientific Reports, 2018, 8, 9021.	1.6	10
13	Efavirenz-associated podocyte damage. Aids, 2007, 21, 257-258.	1.0	9
14	Complement receptor 3 mediates renal protection in experimental C3 glomerulopathy. Kidney International, 2016, 89, 823-832.	2.6	7
15	Baseline characteristics of patients with atypical haemolytic uraemic syndrome (aHUS): The Australian cohort in a global aHUS registry. Nephrology, 2020, 25, 683-690.	0.7	6
16	The perfect storm. Kidney International, 2017, 92, 267.	2.6	3
17	Durable remission of C3 glomerulonephritis with mycophenolate mofetil. Nephrology, 2017, 22, 36-39.	0.7	2
18	SO054ONE-YEAR EFFICACY AND SAFETY OF THE LONG ACTING C5 INHIBITOR RAVULIZUMAB FOR THE TREATMENT OF ATYPICAL HAEMOLYTIC URAEMIC SYNDROME (AHUS) IN ADULTS. Nephrology Dialysis Transplantation, 2020, 35, .	0.4	2

#	Article	IF	Citations
19	Noninfectious mixed cryoglobulinaemic glomerulonephritis and monoclonal gammopathy of undetermined significance: a coincidental association?. BMC Nephrology, 2020, 21, 293.	0.8	2
20	Proliferative Glomerulonephritis With Fibrils, Monoclonal Îº Light Chain, and C3 Deposits. American Journal of Kidney Diseases, 2021, 78, 459-463.	2.1	2
21	Simultaneous necrotizing glomerulonephritis and Hodgkin's lymphoma: a case report and review of the literature. Nephrology Dialysis Transplantation, 2011, 26, 3403-3408.	0.4	1
22	Cat-Scratch Disease Masquerading as C3 Glomerulonephritis. Kidney International Reports, 2020, 5, 2388-2392.	0.4	1
23	Disorders of complement regulation. Drug Discovery Today: Disease Models, 2014, 11, 29-35.	1.2	0